By comparing the proteomes of affected and unaffected family members, researchers have gained new insights into the rare genetic disorder Menkes disease, and found that it has molecular connections to Parkinson's disease (PD).
Data from the phase II SUMMIT basket trial of HER tyrosine kinase inhibitor neratinib (Puma Biotechnology Inc.) in patients with HER2 or HER3-mutated tumors across multiple anatomical locations have shown that targeting HER2 can have therapeutic value in tumors beyond breast cancer, but also reaffirmed that for most targeted therapies, the anatomical location as well as the molecular mutation play a role.
Separate research teams offered insight this week into how Ras-driven pancreatic cancers develop, and reported that a small molecule targeting mutated K-Ras led to tumor regression in patient-derived xenograft mouse models of K-Ras-driven cancers.
Kinase inhibitors are collectively one of the most successful drug classes, but they are challenging to develop in part because their activity usually depends on their overall effect on multiple different kinases.
Scientists have the first primates born from embryos created via somatic cell nuclear transfer (SCNT), more commonly known as cloning, described in Cell.
According to the World Health Organization's (WHO's) Global tuberculosis report 2017, "TB is the ninth leading cause of death worldwide and the leading cause from a single infectious agent, ranking above HIV/AIDS. In 2016, there were an estimated 1.3 million TB deaths among HIV-negative people . . . and an additional 374,000 deaths among HIV-positive people. An estimated 10.4 million people fell ill with TB in 2016."
